Asset profile
ADS051
Small molecule
Evidence outlook · lead readout
NCT05084261 · Ulcerative Colitis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05084261: The study was randomized and blinded with a placebo comparator, but its primary goal was safety and tolerability rather than proving clinical benefit, enrollment was small, and no results have been posted yet.
The sponsor release does not cite the trial's registry number; identity rests on the matching sponsor, dosing cohorts and study design.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.